title: Local injection of a sustained-release antiandrogen formulation into a target prostatic site: an experimental study.
abstract: OBJECTIVE
  To evaluate the efficacy of one intraprostatic injection with sustained-release chlormadinone acetate (CMA-SR) in rats.
  
  
  METHODS
  CMA, a steroidal antiandrogen, was enclosed in microcapsules for sustained-release (CMA-SR). Forty-eight rats were divided into group A (intraprostatic CMA-SR 8 mg/kg, one injection), group B (as A but with 25 mg/kg), group C (intraprostatic, vehicle only) and group D (subcutaneous, s.c., CMA 10 mg/kg once daily for 4 weeks). Prostate weight, body weight and plasma testosterone levels were measured for up to 4 weeks.
  
  
  RESULTS
  After a s.c. injection with CMA-SR, residual CMA at the s.c. injection site decreased with time. The injected prostate lobe weighed significantly (P < 0.05) less than the contralateral lobe in groups A and B, and significantly (P < 0.05) less in groups A and B than in group C. Both prostate lobes in group D were significantly (P < 0.05) smaller than in group C (P < 0.05). Plasma testosterone levels were significantly lower in group D than in group C (P < 0.05).
  
  
  CONCLUSIONS
  The sustained release of CMA after one intraprostatic injection persistently decreased the weight of the target prostate. This new concept of antiandrogen therapy might therefore be effective in man, with fewer systemic adverse reactions.
authors.affiliation: Department of Urology, Tokyo Women's Medical University, Tokyo. goya@kc.twmu.ac.jp
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Goya
authors.forename: Kotaro
authors.initials: K
authors.lastname: Gotanda
authors.forename: Takako
authors.initials: T
authors.lastname: Sasaki
authors.forename: Mami
authors.initials: M
authors.lastname: Okada
authors.forename: Yasuko
authors.initials: Y
authors.lastname: Tomizawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Toma
mesh_terms: D000726:Androgen Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D000818:Animals; D002715:Chlormadinone Acetate / Q000008:administration & dosage* / Q000009:adverse effects; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000009:adverse effects; D007267:Injections; D008297:Male; D009929:Organ Size; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D051381:Rats
chemical_list: D000726:Androgen Antagonists; D003692:Delayed-Action Preparations; D002715:Chlormadinone Acetate